1.Urinary Iodine Content of Children Aged 8—10 years in Qiandongnan, Guizhou Province in 2006
Fang WEI ; Zhuzhou SHAN ; Yuquan ZHANG
Journal of Environment and Health 1992;0(02):-
Objective To understand the iodine nutrition of children in Qiandongnan and to provide the scientific evidence for prevention and control of iodine deficiency disorders (IDD). Methods The 3200 urinary samples of pupils aged 8-10 were collected from 80 primary schools in 16 county and city in Qiandongnan in 2006. The urinary iodine content was tested by colorimetric ceric-arsenic assay and vitriolic ammonium assimilation. Results The median of urinary iodine content in children samples was 362.9?g/L, the percentage of urinary iodine( ≥100?g/L) was 98.00%, in which ≥300?g/L was 65.31%, the percentage of urinary iodine(
2.Progress in Mechanism of Astragalus membranaceus and Its Chemical Constituents on Multiple Sclerosis.
Yong PENG ; Xiang DENG ; Shan-Shan YANG ; Wei NIE ; Yan-Dan TANG
Chinese journal of integrative medicine 2023;29(1):89-95
The primary chemical components of Astragalus membranaceus include polysaccharides, saponins, flavonoids, and amino acids. Recent studies have shown that Astragalus membranaceus has multiple functions, including improving immune function and exerting antioxidative, anti-radiation, anti-tumor, antibacterial, antiviral, and hormone-like effects. Astragalus membranaceus and its extracts are widely used in clinical practice because they have obvious therapeutic effects against various autoimmune diseases and relatively less adverse reaction. Multiple sclerosis (MS) is an autoimmune disease of central nervous system (CNS), which mainly caused by immune disorder that leads to inflammatory demyelination, inflammatory cell infiltration, and axonal degeneration in the CNS. In this review, the authors analyzed the clinical manifestations of MS and experimental autoimmune encephalomyelitis (EAE) and focused on the efficacy of Astragalus membranaceus and its chemical components in the treatment of MS/EAE.
Animals
;
Humans
;
Astragalus propinquus/chemistry*
;
Multiple Sclerosis/drug therapy*
;
Encephalomyelitis, Autoimmune, Experimental/metabolism*
;
Drugs, Chinese Herbal/chemistry*
;
Polysaccharides
3. Genetic characteristic of hemagglutinin of avian influenza A (H7N9) virus in Guizhou Province in 2017
Yonghu WAN ; Li ZHUANG ; Lijuan REN ; Qunni ZHENG ; Lin FU ; Zhuzhou SHAN ; Fengfeng PEI ; Weijia JIANG ; Guangpeng TANG ; Shijun LI
Chinese Journal of Preventive Medicine 2019;53(2):229-232
The number of H7N9 bird flu cases was high and the situation was grim in guizhou province in 2017. To understand the molecular characteristics of the hemagglutinin gene (HA) and the risk of human infection with avian influenza virus A(H7N9) in Guizhou Province, 2017. Homology, genetic evolution and pivotal sites related to receptor binding regions, pathogenicity and potential glycosylation of 14 avian influenza viruses A(H7N9) were analyzed by a series of bioinformation softwares. It was cleared that there was 95.9%-100% similarity among 14 strains in nucleotide of the HA gene, and there were 96.8%-97.8% and 96.8%-97.9% similarities with vaccine strains A/Shanghai/2/2013 and A/Anhui/1/2013 recommended by WHO, respectively. Phylogenetic analysis showed that 14 HA genes were directly evolved in the Yangtze River Delta evolution branch, but they could be derived from five diffenrent strains. Then 13 of 14 strains cleavage site sequences of HA protein revealed they were low pathogenic avian influenza viruses, while A/Guizhou-Weining/CSY01/2017 was high pathogenic avian influenza virus. Mutation G186V at the receptor binding sites in the HA was found in all 14 strains, and mutation Q226L in 13 strains besides A/Guizhou-Weining/CSY01/2017. All five potential glycosylation motifs in the HA were conservative.
4.Mechanism of Cordyceps militaris against non-small cell lung cancer: based on serum metabolomics.
Ying-Ying LU ; Xiao HUANG ; Zi-Chen LUO ; Ming-Yuan QI ; Jin-Jun SHAN ; Wen ZHANG ; Liu-Qing DI
China Journal of Chinese Materia Medica 2022;47(18):5032-5039
This study investigated the potential mechanism of Cordyceps militaris(CM) against non-small cell lung cancer(NSCLC) based on serum untargeted metabolomics. Specifically, Balb/c nude mice were used to generate the human lung cancer A549 xenograft mouse model. The tumor volume, tumor weight, and tumor inhibition rate in mice in the model, cisplatin, Cordyceps(low-, medium-, and high-dose), and CM(low-, medium-, and high-dose) groups were compared to evaluate the influence of CM on lung cancer. Gas chromatography-mass spectrometry(GC-MS) was used for the analysis of mouse serum, SIMCA 13.0 for the compa-rison of metabolic profiles, and MetaboAnalyst 5.0 for the analysis of metabolic pathways. According to the pharmacodynamic data, the tumor volume and tumor weight of mice in high-dose CM group and cisplatin group decreased as compared with those in the model group(P<0.05 or P<0.01). The results of serum metabolomics showed that the metabolic profiles of the model group were significantly different from those of the high-dose CM group, and the content of endogenous metabolites was adjusted to different degrees. A total of 42 differential metabolites and 7 differential metabolic pathways were identified. In conclusion, CM could significantly inhibit the tumor growth of lung cancer xenograft mice. The mechanism is the likelihood that it influences the aminoacyl-tRNA biosynthesis, the metabolism of D-glutamine and D-glutamate, metabolism of alanine, aspartate, and glutamate, metabolism of glyoxylate and dicarboxylic acid, biosynthesis of phenylalanine, tyrosine, and tryptophan, arginine biosynthesis as well as nitrogen metabolism. This study elucidated the underlying mechanism of CM against NSCLC from the point of metabolites. The results would lay a foundation for the anticancer research and clinical application of CM.
Alanine/metabolism*
;
Animals
;
Arginine/metabolism*
;
Aspartic Acid
;
Carcinoma, Non-Small-Cell Lung/drug therapy*
;
Cisplatin/pharmacology*
;
Cordyceps
;
Glutamic Acid
;
Glutamine
;
Glyoxylates/metabolism*
;
Humans
;
Lung Neoplasms/drug therapy*
;
Metabolomics/methods*
;
Mice
;
Mice, Nude
;
Nitrogen/metabolism*
;
Phenylalanine/metabolism*
;
RNA, Transfer/metabolism*
;
Tryptophan/metabolism*
;
Tyrosine/metabolism*